Current and Emerging Pharmacotherapy for Fibromyalgia
Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (...
Saved in:
| Main Authors: | Roie Tzadok, Jacob N. Ablin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Pain Research and Management |
| Online Access: | http://dx.doi.org/10.1155/2020/6541798 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fibromyalgia: are you a genetic/environmental disease?
by: Jacob N. Ablin
Published: (2025-06-01) -
Effects of Workplace-Related Factors on the Prevalence of Fibromyalgia among Israeli Kindergarten Teachers
by: Yafa Buskila, et al.
Published: (2020-01-01) -
Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients
by: Victoria Furer, et al.
Published: (2018-01-01) -
Current therapy of fibromyalgia syndrome
by: N.V. Chichasova, et al.
Published: (2014-05-01) -
Pharmacotherapy of hepatitis D: the current and the future
by: George Sarin Zacharia, et al.
Published: (2025-05-01)